CatalystFDA/Bio

GSK TO ADVANCE MRNA SEASONAL FLU VACCINE TO PHASE 3 TRIAL - SEEKINGALPHA

Phase 3 advancement signals regulatory progress and commercial potential for GSK's mRNA flu vaccine.

What changed

Phase 3 advancement signals regulatory progress and commercial potential for GSK's mRNA flu vaccine.

Why it matters

Phase 3 advancement signals regulatory progress and commercial potential for GSK's mRNA flu vaccine. — impact context not separately stored; see What changed.

Sources

seekingalpha